Scientific Studies
Want to know more about our strains?
Here are studies related to the probiotic strains Lactobacillus acidophila La-14 and Lactobacillus rhamnosus HN001:
-
Probiotic Attenuation of Bacterial Vaginosis: Lactobacillus rhamnosus HN001 and Lactobacillus acidophilus La-14 were shown to attenuate bacterial vaginosis in mice by inhibiting inflammation and promoting immune responses, with oral administration being more effective than intravaginal use (Jang et al., 2017).
-
Antagonistic Activity Against Pathogens: These strains, included in an oral probiotic, exhibited strong antibacterial activity against opportunistic pathogens such as Escherichia coli and Candida albicans. They also demonstrated resistance to common antibiotics, making them effective for preventing dysbiosis (Budilovskaya et al., 2024).
-
Vaginal Microbiota Stability: A randomized controlled trial found that oral supplementation with La-14 and HN001 did not significantly colonize the vagina but maintained stable vaginal microbiota without adverse effects (Lyra et al., 2023).
-
Immune Enhancement: Lactobacillus rhamnosus HN001 significantly enhanced natural immunity, including phagocytic activity and antibody responses, in both animal models and human trials (Gill et al., 2001).
-
Colonization and Vaginal Health: A study reported that oral consumption of La-14 and HN001 (Respecta® complex) led to vaginal detection of these strains and improvement in Nugent scores, which is associated with vaginal health (Alberti et al., 2015).
These studies highlight the potential of these probiotic strains in immune modulation, vaginal health, and combating pathogenic microbes.
Want to see more??? Just Google the following: Scientific studies of probiotic strains Lactobacillus acidophila La-14 and Lactobacillus rhamnosus HN001.
You'll see what we have seen... these two strains are THE BEST to maintain optimal intimate flora